AbbVie seeks EMA approval for Skyrizi subcutaneous induction in Crohn’s disease
ABBV•EMA filing for Skyrizi in Crohn’s disease
AbbVie filed with the EMA seeking approval for SKYRIZI subcutaneous induction in adults with moderately to severely active Crohn’s disease.
The submission is backed by Phase 3 AFFIRM data; the drug already has EU approval for Crohn’s disease with IV induction.
